MET and colorectal carcinoma: Also, SRC activation promoted cetuximab resistance by directly interacting with MET; accordingly, pretreatment with SRC inhibitors abolished cetuximab-mediated MET activation and rendered CRC cells sensitive to cetuximab[90].